AzurRx BioPharma Stock Price, News & Analysis (NASDAQ:AZRX)

$2.73 -0.06 (-2.15 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$2.79
Today's Range$2.70 - $2.93
52-Week Range$2.40 - $5.25
Volume66,921 shs
Average Volume57,165 shs
Market Capitalization$33.56 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.98

About AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma logoAzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855

Debt

Debt-to-Equity RatioN/A
Current Ratio1.16%
Quick Ratio1.16%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.33 per share
Price / Book8.27

Profitability

Trailing EPSN/A
Net Income$-14,590,000.00
Net MarginsN/A
Return on Equity-470.85%
Return on Assets-205.40%

Miscellaneous

Employees8
Outstanding Shares11,610,000

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

When will AzurRx BioPharma make its next earnings announcement?

AzurRx BioPharma is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for AzurRx BioPharma.

Where is AzurRx BioPharma's stock going? Where will AzurRx BioPharma's stock price be in 2018?

1 brokers have issued 12-month target prices for AzurRx BioPharma's stock. Their predictions range from $8.00 to $8.00. On average, they anticipate AzurRx BioPharma's stock price to reach $8.00 in the next year. View Analyst Ratings for AzurRx BioPharma.

Who are some of AzurRx BioPharma's key competitors?

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the folowing people:

  • Edward J. Borkowski CPA, Independent Chairman of the Board (Age 58)
  • Maged S. Shenouda, Chief Financial Officer, Executive Vice President - Corporate Development & Independent Director (Age 53)
  • Daniel Dupret, Chief Scientific Officer (Age 60)
  • Charles J. Casamento, Director (Age 71)
  • Vern Schramm, Director
  • Alastair Riddell, Independent Director (Age 67)

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

Who owns AzurRx BioPharma stock?

AzurRx BioPharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Parsons Capital Management Inc. RI (2.36%) and Ardsley Advisory Partners (0.71%). View Institutional Ownership Trends for AzurRx BioPharma.

Who bought AzurRx BioPharma stock? Who is buying AzurRx BioPharma stock?

AzurRx BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Ardsley Advisory Partners and Parsons Capital Management Inc. RI. View Insider Buying and Selling for AzurRx BioPharma.

How do I buy AzurRx BioPharma stock?

Shares of AzurRx BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AzurRx BioPharma's stock price today?

One share of AzurRx BioPharma stock can currently be purchased for approximately $2.73.

How big of a company is AzurRx BioPharma?

AzurRx BioPharma has a market capitalization of $33.56 million. AzurRx BioPharma employs 8 workers across the globe.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 217, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]


MarketBeat Community Rating for AzurRx BioPharma (AZRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AzurRx BioPharma (NASDAQ:AZRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$7.50$7.50
Price Target Upside: 134.60% upside134.60% upside158.62% upside108.33% upside

AzurRx BioPharma (NASDAQ:AZRX) Consensus Price Target History

Price Target History for AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma (NASDAQ:AZRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018HC WainwrightSet Price TargetBuy$8.00LowView Rating Details
12/6/2016WallachBeth CapitalInitiated CoverageBuy$7.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

AzurRx BioPharma (NASDAQ:AZRX) Earnings History and Estimates Chart

Earnings by Quarter for AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma (NASDAQ AZRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018        
11/13/2017Q3 2017($0.15)($0.28)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.27)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.29)ViewN/AView Earnings Details
11/25/2016Q3 2016($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AzurRx BioPharma (NASDAQ:AZRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-0.81 EPS

Dividends

Dividend History for AzurRx BioPharma (NASDAQ:AZRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AzurRx BioPharma (NASDAQ AZRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 8.44%
Insider Trades by Quarter for AzurRx BioPharma (NASDAQ:AZRX)
Institutional Ownership by Quarter for AzurRx BioPharma (NASDAQ:AZRX)

AzurRx BioPharma (NASDAQ AZRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2017Pelican Partners LlcMajor ShareholderSell160,000$3.19$510,400.001,787,796View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AzurRx BioPharma (NASDAQ AZRX) News Headlines

Source:
DateHeadline
 Brokerages Set $8.83 Price Target for AzurRx BioPharma Inc (AZRX) Brokerages Set $8.83 Price Target for AzurRx BioPharma Inc (AZRX)
www.americanbankingnews.com - February 21 at 12:05 PM
Novartis (NVS) versus AzurRx BioPharma (AZRX) Head-To-Head SurveyNovartis (NVS) versus AzurRx BioPharma (AZRX) Head-To-Head Survey
www.americanbankingnews.com - February 17 at 7:32 PM
AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SDAzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD
finance.yahoo.com - February 12 at 9:00 AM
AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)
finance.yahoo.com - February 9 at 9:07 AM
Head to Head Contrast: AzurRx BioPharma (AZRX) and Its RivalsHead to Head Contrast: AzurRx BioPharma (AZRX) and Its Rivals
www.americanbankingnews.com - February 6 at 5:10 PM
Zacks: AzurRx BioPharma Inc (AZRX) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: AzurRx BioPharma Inc (AZRX) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 6 at 9:14 AM
AzurRx BioPharma Inc (AZRX) Expected to Post FY2017 Earnings of ($1.03) Per ShareAzurRx BioPharma Inc (AZRX) Expected to Post FY2017 Earnings of ($1.03) Per Share
www.americanbankingnews.com - February 2 at 7:42 AM
AzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.24 Per ShareAzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - February 1 at 1:28 PM
 AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from Brokerages AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 31 at 1:18 AM
SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00
finance.yahoo.com - January 30 at 9:26 AM
Comparing AzurRx BioPharma (AZRX) and The CompetitionComparing AzurRx BioPharma (AZRX) and The Competition
www.americanbankingnews.com - January 28 at 9:26 AM
Financial Analysis: AzurRx BioPharma (AZRX) versus The CompetitionFinancial Analysis: AzurRx BioPharma (AZRX) versus The Competition
www.americanbankingnews.com - January 27 at 11:18 PM
Contrasting AzurRx BioPharma (AZRX) & The CompetitionContrasting AzurRx BioPharma (AZRX) & The Competition
www.americanbankingnews.com - January 27 at 9:14 PM
AzurRx BioPharma (AZRX) and XenoPort (XNPT) Head to Head AnalysisAzurRx BioPharma (AZRX) and XenoPort (XNPT) Head to Head Analysis
www.americanbankingnews.com - January 27 at 5:20 PM
Zacks: AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from AnalystsZacks: AzurRx BioPharma Inc (AZRX) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 25 at 3:14 PM
 AzurRx BioPharma Inc (AZRX) Given $8.25 Average Price Target by Brokerages AzurRx BioPharma Inc (AZRX) Given $8.25 Average Price Target by Brokerages
www.americanbankingnews.com - January 20 at 9:16 PM
AzurRx BioPharma (AZRX) PT Set at $8.00 by HC WainwrightAzurRx BioPharma (AZRX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - January 20 at 6:56 PM
AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic InsufficiencyAzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency
finance.yahoo.com - January 18 at 11:50 AM
AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of WarrantsAzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants
finance.yahoo.com - January 17 at 10:38 AM
AzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.23 Per ShareAzurRx BioPharma Inc (AZRX) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 15 at 1:14 PM
Head to Head Comparison: AzurRx BioPharma (AZRX) and Its CompetitorsHead to Head Comparison: AzurRx BioPharma (AZRX) and Its Competitors
www.americanbankingnews.com - January 12 at 7:02 PM
AzurRx BioPharma (AZRX) & Its Peers Head to Head ComparisonAzurRx BioPharma (AZRX) & Its Peers Head to Head Comparison
www.americanbankingnews.com - January 10 at 12:12 PM
Reviewing AzurRx BioPharma (AZRX) & Its CompetitorsReviewing AzurRx BioPharma (AZRX) & Its Competitors
www.americanbankingnews.com - January 9 at 11:16 PM
 Brokerages Set $8.25 Target Price for AzurRx BioPharma Inc (AZRX) Brokerages Set $8.25 Target Price for AzurRx BioPharma Inc (AZRX)
www.americanbankingnews.com - January 5 at 5:50 PM
Zacks: AzurRx BioPharma Inc (AZRX) Given $8.25 Consensus Target Price by AnalystsZacks: AzurRx BioPharma Inc (AZRX) Given $8.25 Consensus Target Price by Analysts
www.americanbankingnews.com - January 2 at 9:14 PM
AzurRx BioPharma (AZRX) Announces Publication of U.S. Patent Application for AZX1101AzurRx BioPharma (AZRX) Announces Publication of U.S. Patent Application for AZX1101
www.streetinsider.com - December 20 at 10:48 AM
Zacks: AzurRx BioPharma Inc (AZRX) Given Consensus Rating of "Strong Buy" by AnalystsZacks: AzurRx BioPharma Inc (AZRX) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 18 at 1:52 AM
AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)
finance.yahoo.com - December 4 at 10:48 AM
Zacks: AzurRx BioPharma Inc (AZRX) Receives Average Rating of "Strong Buy" from BrokeragesZacks: AzurRx BioPharma Inc (AZRX) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 3 at 9:30 AM
AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th)AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th)
finance.yahoo.com - December 1 at 5:59 PM
Why AzurRx BioPharma Inc’s (AZRX) Investor Composition Impacts Your ReturnsWhy AzurRx BioPharma Inc’s (AZRX) Investor Composition Impacts Your Returns
finance.yahoo.com - December 1 at 5:59 PM
Head-To-Head Survey: GlaxoSmithKline plc (GSK) and AzurRx BioPharma (AZRX)Head-To-Head Survey: GlaxoSmithKline plc (GSK) and AzurRx BioPharma (AZRX)
www.americanbankingnews.com - November 25 at 3:26 AM
Azurrx Biopharm (AZRX) Given a $8.00 Price Target by HC Wainwright AnalystsAzurrx Biopharm (AZRX) Given a $8.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - November 18 at 10:22 AM
 Azurrx Biopharm (AZRX) Given Average Recommendation of "Strong Buy" by Brokerages Azurrx Biopharm (AZRX) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 18 at 9:42 AM
Azurrx Biopharm (AZRX) vs. Theravance Biopharma (TBPH) Critical AnalysisAzurrx Biopharm (AZRX) vs. Theravance Biopharma (TBPH) Critical Analysis
www.americanbankingnews.com - November 7 at 11:08 PM
Equity offering registration roundup - healthcareEquity offering registration roundup - healthcare
seekingalpha.com - November 2 at 9:57 PM
Azurrx Biopharms (AZRX) "Buy" Rating Reiterated at HC WainwrightAzurrx Biopharm's (AZRX) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - October 23 at 9:08 AM
AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) SubmissionAzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission
finance.yahoo.com - October 20 at 6:07 PM
AzurRx BioPharma (AZRX) Appoints Dr. Vern Schramm to BoardAzurRx BioPharma (AZRX) Appoints Dr. Vern Schramm to Board
www.streetinsider.com - October 17 at 3:14 AM
AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of DirectorsAzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors
finance.yahoo.com - October 16 at 5:09 PM
AzurRx BioPharma files for $10M mixed shelf offeringAzurRx BioPharma files for $10M mixed shelf offering
seekingalpha.com - October 12 at 10:09 PM
Healthcare Industry Trends And Its Impact On AzurRx BioPharma Inc (AZRX)Healthcare Industry Trends And Its Impact On AzurRx BioPharma Inc (AZRX)
finance.yahoo.com - October 11 at 5:49 PM
AZRX: Update on MS1819 Phase II TrialAZRX: Update on MS1819 Phase II Trial
finance.yahoo.com - October 2 at 4:15 PM
Azurrx Biopharm (AZRX) Rating Reiterated by HC WainwrightAzurrx Biopharm (AZRX) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 28 at 8:20 PM
AzurRx BioPharma (AZRX) Names Maged Shenouda as CFO - StreetInsider.comAzurRx BioPharma (AZRX) Names Maged Shenouda as CFO - StreetInsider.com
www.streetinsider.com - September 28 at 12:45 AM
AzurRx BioPharma (AZRX), Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in EPI - StreetInsider.comAzurRx BioPharma (AZRX), Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in EPI - StreetInsider.com
www.streetinsider.com - September 28 at 12:45 AM
AZRX: Fall Data Announcement for MS 1819AZRX: Fall Data Announcement for MS 1819
finance.yahoo.com - August 28 at 9:19 PM
AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12
finance.yahoo.com - August 24 at 4:23 PM
Azurrx Biopharm (AZRX) PT Set at $8.00 by HC WainwrightAzurrx Biopharm (AZRX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - August 24 at 2:48 PM
AzurRx BioPharma (AZRX) Reports 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of EPI Associated with CPAzurRx BioPharma (AZRX) Reports 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of EPI Associated with CP
www.streetinsider.com - August 23 at 9:26 PM

SEC Filings

AzurRx BioPharma (NASDAQ:AZRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AzurRx BioPharma (NASDAQ:AZRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AzurRx BioPharma (NASDAQ AZRX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.